ArticleTranslational lung cancer research2025
Immune checkpoint inhibitors combined with chemotherapy as first-line treatment may improve clinical outcomes in advanced non-small cell lung cancer with bone metastases.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bone metastases are common in patients with non-small cell lung cancer (NSCLC) and are associated with a poor prognosis. Although immune checkpoint inhibitors (ICIs), with or without chemotherapy, are the standard first-line treatment for advanced NSCLC, studies directly comparing their effectiveness in patients with bone metastases remain limited. With the present study, we aimed to compare the clinical effectiveness and safety of ICI monotherapy versus ICI plus chemotherapy as first-line treatments for patients with NSCLC and bone metastases. Methods: We retrospectively analyzed 97 patients with NSCLC with bone metastases who underwent first-line treatment with ICIs and divided them into the ICI monotherapy (ICI group: n=44) and combination therapy (ICI-chemo group: n=53) groups. Primary outcomes included the bone metastasis and lung lesion response rates, overall survival (OS), progression-free survival (PFS), and the incidence of skeletal-related events (SREs) and immune-related adverse events (irAEs). Results: The bone metastasis response rate was significantly higher in the ICI-chemo group than that in the ICI group (43.4% Conclusions: The combination of ICIs with chemotherapy as first-line treatment for patients with NSCLC and bone metastases may be associated with an improved response of bone metastases and better prognosis, while exhibiting a comparable safety profile to ICI monotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.